Adverse event comparison between glucagon-like peptide-1 receptor agonists and other antiobesity medications following bariatric surgery.

Samuels JM, Niswender KD, Roumie CL, Spann MD, Flynn CR, Ye F, Blankush J, Irlmeier R, Funk LM, Patel MB

Diabetes, obesity & metabolism27 Jun 2024Cited by 5 (Europe PMC)

PMID38934217PMCIDPMC12223922DOI10.1111/dom.15737PepBankPUB-38934217

Read at source PubMedAsk about this study

Summary

The text of this summary is not shown here, because the article license does not allow reuse. Read it at the source (opens in a new tab)

Text rights: CC BY-NC-ND. Results still quote short attributed sentences.

Results from this study6

No result from this study comes from a test of the peptide.

Studies that did not test the peptide alone6

In this study, the peptide was a lab tool or a carrier, part of a mix, or the subject of a lab method. These results are not evidence about taking the peptide.

01HumanNot a test of Liraglutide aloneObservational studySafety outcome
In patients after bariatric surgery, pooled GLP-1RA antiobesity medications were not associated with higher odds of adverse events than FDA-approved non-GLP-1RA medications (adjusted odds ratio 1.1).
In plain wordsAfter bariatric surgery, GLP-1 drugs as a group were not linked to more side effects than approved non-GLP-1 weight-loss drugs.
Peptide
Liraglutide
Outcome
No significant changeAdverse events after bariatric surgery
Study
n: not reported in source
Comparator
FDA-approved non-GLP-1RA antiobesity medications
Analysis
Primary
Outcome group
Adverse events · Whole body
Measurements
aOR
1.1
GLP-1RA vs FDA-approved AOM
Source sentences
Summary
GLP-1RAs use was not associated with higher odds of AEs: adjusted odds ratio (aOR) 1.1 (95% confidence interval [CI] 0.5-2.6) and aOR 1.1 (95% CI 0.6-2.3) for GLP-1RA versus FDA-approved and off-label AOM use, respectively.
1 context sentence(design, population, supporting numbers)
Summary · context
This single-centre retrospective cohort included patients (aged 16-65 years) who had undergone laparoscopic Roux-en-Y gastric bypass or sleeve gastrectomy (cohort entry date) and initiated AOMs.
In this study, Liraglutide was a lab tool or a carrier, part of a mix, or the subject of a lab method. This result is not evidence about taking Liraglutide.
Report a problemFND-3893421701
02HumanNot a test of Liraglutide aloneObservational studySafety outcome
In patients after bariatric surgery, pooled GLP-1RA antiobesity medications were not associated with higher odds of adverse events than off-label non-GLP-1RA medications (adjusted odds ratio 1.1).
In plain wordsAfter bariatric surgery, GLP-1 drugs as a group were not linked to more side effects than off-label non-GLP-1 weight-loss drugs.
Peptide
Liraglutide
Outcome
No significant changeAdverse events after bariatric surgery
Study
n: not reported in source
Comparator
Off-label non-GLP-1RA antiobesity medications
Analysis
Primary
Outcome group
Adverse events · Whole body
Measurements
aOR
1.1
GLP-1RA vs off-label AOM
Source sentences
Summary
GLP-1RAs use was not associated with higher odds of AEs: adjusted odds ratio (aOR) 1.1 (95% confidence interval [CI] 0.5-2.6) and aOR 1.1 (95% CI 0.6-2.3) for GLP-1RA versus FDA-approved and off-label AOM use, respectively.
1 context sentence(design, population, supporting numbers)
Summary · context
This single-centre retrospective cohort included patients (aged 16-65 years) who had undergone laparoscopic Roux-en-Y gastric bypass or sleeve gastrectomy (cohort entry date) and initiated AOMs.
In this study, Liraglutide was a lab tool or a carrier, part of a mix, or the subject of a lab method. This result is not evidence about taking Liraglutide.
Report a problemFND-3893421702
03HumanNot a test of Semaglutide aloneObservational studySafety outcome
In patients after bariatric surgery, pooled GLP-1RA antiobesity medications were not associated with higher odds of adverse events than FDA-approved non-GLP-1RA medications (adjusted odds ratio 1.1).
In plain wordsAfter bariatric surgery, GLP-1 drugs as a group were not linked to more side effects than approved non-GLP-1 weight-loss drugs.
Peptide
Semaglutide
Outcome
No significant changeAdverse events after bariatric surgery
Study
n: not reported in source
Comparator
FDA-approved non-GLP-1RA antiobesity medications
Analysis
Primary
Outcome group
Adverse events · Whole body
Measurements
aOR
1.1
GLP-1RA vs FDA-approved AOM
Source sentences
Summary
GLP-1RAs use was not associated with higher odds of AEs: adjusted odds ratio (aOR) 1.1 (95% confidence interval [CI] 0.5-2.6) and aOR 1.1 (95% CI 0.6-2.3) for GLP-1RA versus FDA-approved and off-label AOM use, respectively.
1 context sentence(design, population, supporting numbers)
Summary · context
This single-centre retrospective cohort included patients (aged 16-65 years) who had undergone laparoscopic Roux-en-Y gastric bypass or sleeve gastrectomy (cohort entry date) and initiated AOMs.
In this study, Semaglutide was a lab tool or a carrier, part of a mix, or the subject of a lab method. This result is not evidence about taking Semaglutide.
Report a problemFND-3893421703
04HumanNot a test of Semaglutide aloneObservational studySafety outcome
In patients after bariatric surgery, pooled GLP-1RA antiobesity medications were not associated with higher odds of adverse events than off-label non-GLP-1RA medications (adjusted odds ratio 1.1).
In plain wordsAfter bariatric surgery, GLP-1 drugs as a group were not linked to more side effects than off-label non-GLP-1 weight-loss drugs.
Peptide
Semaglutide
Outcome
No significant changeAdverse events after bariatric surgery
Study
n: not reported in source
Comparator
Off-label non-GLP-1RA antiobesity medications
Analysis
Primary
Outcome group
Adverse events · Whole body
Measurements
aOR
1.1
GLP-1RA vs off-label AOM
Source sentences
Summary
GLP-1RAs use was not associated with higher odds of AEs: adjusted odds ratio (aOR) 1.1 (95% confidence interval [CI] 0.5-2.6) and aOR 1.1 (95% CI 0.6-2.3) for GLP-1RA versus FDA-approved and off-label AOM use, respectively.
1 context sentence(design, population, supporting numbers)
Summary · context
This single-centre retrospective cohort included patients (aged 16-65 years) who had undergone laparoscopic Roux-en-Y gastric bypass or sleeve gastrectomy (cohort entry date) and initiated AOMs.
In this study, Semaglutide was a lab tool or a carrier, part of a mix, or the subject of a lab method. This result is not evidence about taking Semaglutide.
Report a problemFND-3893421704
05HumanNot a test of Dulaglutide (Trulicity) aloneObservational studySafety outcome
After bariatric surgery, pooled GLP-1RA use, including dulaglutide, was not linked to higher adverse-event odds than FDA-approved non-GLP-1RA medications.
In plain wordsAfter bariatric surgery, pooled GLP-1RA use was not linked to higher adverse-event odds than FDA-approved non-GLP-1RA medications.
Peptide
Dulaglutide (Trulicity)
Outcome
No significant changeAdverse events
Study
n: not reported in source
Comparator
FDA-approved non-GLP-1RA antiobesity medications
Analysis
Primary
Outcome group
Adverse events · Whole body
Measurements
Adjusted odds ratio
1.1 ratio
GLP-1RA versus FDA-approved AOM
Source sentences
Summary
GLP-1RAs use was not associated with higher odds of AEs: adjusted odds ratio (aOR) 1.1 (95% confidence interval [CI] 0.5-2.6) and aOR 1.1 (95% CI 0.6-2.3) for GLP-1RA versus FDA-approved and off-label AOM use, respectively.
2 context sentences(design, population, supporting numbers)
Summary · context
This single-centre retrospective cohort included patients (aged 16-65 years) who had undergone laparoscopic Roux-en-Y gastric bypass or sleeve gastrectomy (cohort entry date) and initiated AOMs.
Summary · context
GLP-1RA AOMs included: semaglutide, dulaglutide, exenatide and liraglutide.
In this study, Dulaglutide (Trulicity) was a lab tool or a carrier, part of a mix, or the subject of a lab method. This result is not evidence about taking Dulaglutide (Trulicity).
Report a problemFND-3893421705
06HumanNot a test of Dulaglutide (Trulicity) aloneObservational studySafety outcome
After bariatric surgery, pooled GLP-1RA use, including dulaglutide, was not linked to higher adverse-event odds than off-label non-GLP-1RA medications.
In plain wordsAfter bariatric surgery, pooled GLP-1RA use was not linked to higher adverse-event odds than off-label non-GLP-1RA medications.
Peptide
Dulaglutide (Trulicity)
Outcome
No significant changeAdverse events
Study
n: not reported in source
Comparator
Off-label non-GLP-1RA antiobesity medications
Analysis
Primary
Outcome group
Adverse events · Whole body
Measurements
Adjusted odds ratio
1.1 ratio
GLP-1RA versus off-label AOM
Source sentences
Summary
GLP-1RAs use was not associated with higher odds of AEs: adjusted odds ratio (aOR) 1.1 (95% confidence interval [CI] 0.5-2.6) and aOR 1.1 (95% CI 0.6-2.3) for GLP-1RA versus FDA-approved and off-label AOM use, respectively.
2 context sentences(design, population, supporting numbers)
Summary · context
This single-centre retrospective cohort included patients (aged 16-65 years) who had undergone laparoscopic Roux-en-Y gastric bypass or sleeve gastrectomy (cohort entry date) and initiated AOMs.
Summary · context
GLP-1RA AOMs included: semaglutide, dulaglutide, exenatide and liraglutide.
In this study, Dulaglutide (Trulicity) was a lab tool or a carrier, part of a mix, or the subject of a lab method. This result is not evidence about taking Dulaglutide (Trulicity).
Report a problemFND-3893421706

AI wrote and checked these results. AI can make mistakes, so check important results against the source.

Version history

PepBank keeps every version of the data on this study. Status changes from Retraction Watch, Europe PMC and Crossref are listed with their source.

Versions 5 to 10Current
28 Oct 2026, 02:03 UTC
The same notice was added 6 times, first on 22 Oct 2026, 02:26 UTC. The status did not change between them.
Study results updated
Version 4
21 Oct 2026, 18:59 UTC
Study data updated · source update from Europe PMC
Version 3
12 Oct 2026, 11:11 UTC
Study results updated
Version 2
9 Oct 2026, 03:06 UTC
Study data updated · source update from Europe PMC
Version 1
9 Oct 2026, 03:05 UTC
First added · source update from Europe PMC

PepBank is a research reference. Talk to a doctor before you use any peptide.

Adverse event comparison between glucagon-like peptide-1 receptor agonists and other antiobesity medications following bariatric surgery.

Summary

Results from this study6

Studies that did not test the peptide alone6

Version history

Subjects

Publication types

MeSH terms

Keywords